慢性精神分裂应用阿立哌唑治疗的临床效果分析

Clinical Efficacy of Aripiprazole in the Treatment of Chronic Schizophrenia

目的分析慢性精神分裂应用阿立哌唑治疗的效果。方法选取2014年8月—2017年8月我院收治慢性精神分裂患者92例作为研究对象,采用数表法,将其随机分成两组。采用利培酮治疗的45例患者作为对照组,采用阿立哌唑治疗的47例患者作为试验组,观察和比较两组结果。结果试验组患者的缓解率为95.7%,比对照组的80.0%高。试验组患者的试验组患者的不良反应发生率为6.4%,比对照组的22.2%低,差异具有统计学意义(P <0.05);治疗后,试验组PANSS评分(63.01±6.39)分,比对照组的(72.33±9.65)分低。PSP评分(62.08±4.97)分,比对照组的(50.02±4.16)分高,差异具有统计学意义(P <0.05)。结论给予慢性精神分裂患者阿立哌唑治疗,有助于改善精神状态,提高治疗效果和生活质量。

Objective To analyze the effect of aripiprazole in the treatment of chronic schizophrenia. Methods 92 patients with chronic schizophrenia in our hospital from August 2014 to August 2017 were selected as the subjects of study. They were randomly divided into two groups by table method. 45 patients treated with risperidone served as control group. 47 patients were treated with aripiprazole as the experimental group. The results of the two groups were observed and compared. Results The remission rate of the experimental group was 95.7%, which was higher than 80.0% of the control group. The incidence of adverse reactions was 6.4% in the experimental group, which was lower than 22.2% in the control group (P < 0.05). After treatment, the PANSS score of the experimental group (63.01±6.39) points was lower than that of the control group (72.33±9.65) points. The PSP score (62.08±4.97) points was higher than that of the control group (50.02±4.16) points, and the difference was statistically significant (P < 0.05). Conclusion Aripiprazole treatment for chronic schizophrenia patients is helpful to improve mental status, improve the treatment effect and quality of life.